Entity family
Named diseases, disorders, syndromes, injuries, and health conditions. Examples include epilepsy, diabetes, stroke.
This disease is selected. Its supporting articles are shown below.
…bjective response rate (ORR).Results Twenty-seven patients with PD-L1-negative NSCLC treated with chemoimmunotherapy were included. At a median foll…
…ageal cancer, 10 with gastric cancer, 39 with melanoma, 45 with non-small-cell lung cancer, 41 with renal cancer, seven with urothelial bladder cancer, an…
…cines. 2023;11(2):508.Liu C, Huang Y, Cui Z, et al. KRAS-mutant non-small cell lung cancer: from molecular heterogeneity to clinical management. Cancer Co…
…Background Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related deaths, often diag…
… during dose-escalation (21%; n=19), and in the CPI-experienced melanoma (8%, n=38) and CPI-naïve ESCC (20%, n=15) expansion cohorts.Con…
…with melanoma, 100 with non-small-cell lung cancer, and 11 with renal cancer. Reduced dose pembrolizumab was prescribed in 82% (192 out of 2…
…a cornerstone in the treatment of several cancers, particularly solid tumours. Recent evidence suggests that the timing of administration may…
…x (PNI), and lactate dehydrogenase (LDH) levels in very elderly NSCLC patients receiving immune checkpoint inhibitors (ICIs), and its…
…ancer types were colorectal (28; 25.0%), breast (26; 23.2%) and non-small-cell lung cancer (20; 17.9%).Overall, 104 (92.9%) patients reported HP use. 73 (…
…a cardiovascular history.Conclusion and Relevance Patients with NSCLC treated with oral antineoplastic agents exhibit a high baseline…
…cases of cardiotoxicity induced by osimertinib in patients with non-small-cell lung cancer (NSCLC). However, limited data exist for a comprehensive cardio…
…plet study of plinabulin/docetaxel/pembrolizumab for metastatic NSCLC immediately after progression on immune-checkpoint-inhibitor al…